PIANO
Financiado
Nanoparticle Based Imaging and Therapy of Chronic Pain in the Dorsal Root Gangli...
Chronic pain is a debilitating disease, which affects approximately 1.5 billion people worldwide, and of those, approximately
4% suffer from neuropathic pain. Neuropathic pain is often described as a shooting or burning pain that...
Chronic pain is a debilitating disease, which affects approximately 1.5 billion people worldwide, and of those, approximately
4% suffer from neuropathic pain. Neuropathic pain is often described as a shooting or burning pain that can come and then
disappear but equally it may become chronic, where the pain may become unrelenting and severe. It often is the result of
nerve damage or a malfunctioning nervous system. Additionally there is the impact upon society where the costs related to
disability allowance, treatment, lost wages and productivity impacts the economy. Current treatments for chronic pain are not
fully reliable and there is a severe lack of tools to diagnose or visualise the pain process within the dorsal root ganglia
(DRG). Humans have 62 DRGs which are the first relay stations in the pain pathway. Local targeted treatment at the level of
those DRGs involved in the pain process is the solution to circumvent side effects and optimise treatment. We aim to identify
involved DRGs by visualising cells or molecules in the DRG which are directly or indirectly associated with the generation of
pain. We will use a novel method of nanoparticles targeted towards pain-associated cells or molecules in the DRG. A vast
amount of neuropathic pain studies have shown an eminent infiltration of macrophages into affected DRGs. These
nanoparticles will be specifically designed to target initially the macrophages in the DRG, encapsulating both therapeutic
payloads and imaging contrast reagents to monitor pain-associated activities. The goal of PIANO is therefore to facilitate a
state-of-art approach to visualisation of neuropathic pain / inflammation at DRG sites as well as to simultaneously release
analgesic molecules from the nanoparticles.
ver más
Duración del proyecto: 51 meses
Fecha Inicio: 2020-11-09
Fecha Fin: 2025-02-28
Fecha Fin: 2025-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-11-09
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-ITN-2020:
Innovative Training Networks
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
KINGS COLLEGE LONDON
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
523.00K€ |
Participante